SANDBOX-&-CO
5.10.2022 14:01:50 CEST | Business Wire | Press release
Sandbox & Co, a London-based group operating a network of learning businesses, today announced that it has acquired award-winning UK-based children’s subscription service, toucanBox, which will sit within its newest division, Sandbox Experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005015/en/
Virginie Charles-Dear, Founder and CEO of toucanBox, UK-based children’s subscription service, that is now part of Sandbox & Co.’s rapidly expanding portfolio (Photo: Business Wire)
Inspired by Montessori learning and championing STEAM (science, technology, engineering, art, and maths), the newly acquired toucanBox provides fun educational opportunities for children aged 3 to 8 yrs. Through custom boxes posted through the letterbox, on a subscription or buy it now basis, it delivers craft materials and activities that help develop children’s key skills and support their cognitive and language development, fine motor skills and mental wellbeing.
‘We have been big fans of toucanBox and feel it is a perfect complement to our existing range of hands-on educational tools.’ said Bhav Singh, founder and CEO of Sandbox. ‘Creativity-filled fun learning is at the heart of what we do and I can’t wait to start working together on new experiences that will keep our users delighted and entertained.’
toucanBox will be joining the company’s new division, Sandbox Experiences, that currently includes Brazilian children’s book club, Leiturinha. Drawing on his expertise in growing Leiturinha into the largest kids book subscription service in Brazil, Sandbox Experiences’ lead, Guilherme Martins, will be focusing on rolling out new products across new markets, including in the USA and Europe.
‘Our goal is to deliver fun-filled learning opportunities for children aged 0-12 around the world’, said Guilherme Martins, president at Sandbox Experiences. ‘toucanBox is the perfect extension to our existing offering and I look forward to collaborating with the team on delivering even more engaging educational opportunities to help improve learning worldwide.’
‘toucanBox is all about learning through hands-on, fun activities and we are excited to join forces with Sandbox to accelerate our growth and pursue our mission to unleash children’s creativity’, said Virginie Charles-Dear, Founder and CEO of toucanBox. ‘We’re looking forward to expanding our product range further and reaching even more families in Europe and across the world.’
Sandbox has seen rapid growth over the last 5 years, and its current portfolio now consists of 18 brands with a peak monthly audience of 65M+ kids, families, and teachers. Its award-winning properties include Code Kingdoms, online coding courses for kids, Hopster, preschool learning platform, and Spanish companies Edujoy and Tellmewow. The company has been acquisitive and continues to focus on its buy and build strategy.
For logo and images click HERE
About Sandbox & Co – https://sandboxandco.com
Sandbox & Co is a London-based group operating a network of learning businesses providing an unparalleled ecosystem of edutainment products that reaches over 65 million children, their parents, and teachers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom